Perrigo Company PLC (PRGO)
Stock Price Chart
Key Info
| Market Cap | 7.23B |
| Revenue (ttm) | 5.00B |
| Net Income (ttm) | 188.60M |
| Shares Out | 136.31M |
| EPS (ttm) | 1.37 |
| PE Ratio | 38.70 |
| Forward PE | 14.20 |
| Dividend | $0.90 |
| Dividend Yield | 1.70% |
Stock Quote
| Trading Day | Jul 31, 2020 |
| Last Price | $53.02 |
| Previous Close | $54.78 |
| Change ($) | -1.76 |
| Change (%) | -3.21% |
| Day's Open | 54.86 |
| Day's Range | 52.72 - 54.87 |
| Day's Volume | 1,111,218 |
| 52-Week Range | 40.01 - 63.86 |
More Stats
| Market Cap | 7.23B |
| Enterprise Value | 10.19B |
| Earnings Date (est) | Aug 5, 2020 |
| Ex-Dividend Date | May 28, 2020 |
| Shares Outstanding | 136.31M |
| Float | 135.93M |
| EPS (basic) | 1.39 |
| EPS (diluted) | 1.37 |
| FCF / Share | 2.31 |
| Dividend | $0.90 |
| Dividend Yield | 1.70% |
| Earnings Yield | 2.58% |
| FCF Yield | 4.35% |
| Payout Ratio | 61.50% |
| Shares Short | 3.89M |
| Short Ratio | 5.04 |
| Short % of Float | 3.88% |
| Beta | 1.21 |
| PE Ratio | 38.70 |
| Forward PE | 14.20 |
| P/FCF Ratio | 22.96 |
| PS Ratio | 1.44 |
| PB Ratio | 1.32 |
| Revenue | 5.00B |
| Operating Income | 248.20M |
| Net Income | 188.60M |
| Free Cash Flow | 314.70M |
| Net Cash | -2.96B |
| Net Cash / Share | -21.72 |
| Gross Margin | 35.44% |
| Operating Margin | 4.96% |
| Profit Margin | 3.80% |
| FCF Margin | 6.29% |
| ROA | 2.63% |
| ROE | 3.28% |
| ROIC | 5.80% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,837 | 4,732 | 4,946 | 5,281 | 4,227 | 3,914 | 3,540 | 3,173 | 2,755 | 2,268 |
| Revenue Growth | 2.23% | -4.34% | -6.33% | 24.92% | 8% | 10.57% | 11.55% | 15.18% | 21.46% | - |
| Gross Profit | 1,773 | 1,832 | 1,980 | 2,052 | 1,644 | 1,452 | 1,280 | 1,096 | 945 | 746 |
| Operating Income | 205 | 237 | 598 | -2,000 | 673 | 571 | 679 | 569 | 490 | 336 |
| Net Income | 146 | 131 | 120 | -4,013 | 136 | 233 | 442 | 402 | 339 | 224 |
| Shares Outstanding | 136 | 138 | 142 | 143 | 139 | 115 | 93.90 | 93.20 | 92.30 | 91.40 |
| Earnings Per Share | 1.07 | 0.95 | 0.84 | -28.01 | 0.97 | 2.01 | 4.68 | 4.27 | 3.63 | 2.41 |
| EPS Growth | 12.63% | 13.1% | - | - | -51.74% | -57.05% | 9.6% | 17.63% | 50.62% | - |
| Dividend Per Share | 0.82 | 0.76 | 0.64 | 0.58 | 0.46 | 0.39 | 0.35 | 0.31 | 0.27 | 0.24 |
| Dividend Growth | 7.89% | 18.75% | 10.34% | 26.09% | 17.95% | 11.43% | 12.9% | 13.55% | 12.81% | - |
| Operating Cash Flow | 388 | 593 | 699 | 655 | 855 | 633 | 554 | 513 | 374 | 332 |
| Capital Expenditures | -138 | -103 | -88.60 | -106 | -137 | -172 | -104 | -110 | -99.40 | -57.82 |
| Free Cash Flow | 250 | 490 | 610 | 549 | 718 | 461 | 450 | 404 | 275 | 275 |
| Cash & Equivalents | 354 | 551 | 679 | 622 | 786 | 800 | 780 | 603 | 310 | 510 |
| Total Debt | 3,369 | 3,242 | 3,341 | 5,797 | 5,400 | 3,207 | 1,974 | 1,369 | 893 | 1,344 |
| Net Cash / Debt | -3,015 | -2,691 | -2,663 | -5,175 | -4,615 | -2,407 | -1,194 | -767 | -583 | -834 |
| Assets | 11,301 | 10,983 | 11,629 | 13,870 | 19,592 | 13,853 | 5,351 | 4,024 | 3,189 | 3,109 |
| Liabilities | 5,497 | 5,315 | 5,458 | 7,913 | 8,892 | 5,159 | 3,018 | 2,171 | 1,658 | 2,015 |
| Book Value | 5,804 | 5,668 | 6,171 | 5,958 | 10,699 | 8,693 | 2,333 | 1,853 | 1,531 | 1,094 |
Company Profile
Company Details
| Full Name | Perrigo Company PLC |
| Country | Ireland |
| Employees | 11,000 |
| CEO | Murray S. Kessler |
Stock Information
| Ticker Symbol | PRGO |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: PRGO |
| IPO Date | December 16, 1991 |
Description
Perrigo Company plc manufactures and supplies over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. It provides upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Steripod, and Rembrandt brand names. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force. Perrigo Co. plc has a partnership with NetworkWire to license Witi's patent-pending hardware and software IP in development of a smoking cessation product. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.